Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group

Journal of Clinical Oncology

Volumn 12, Issue 11, 1994, Pages 2264-2270

  Roth, Bruce J ^a   Dreicer, Robert ^b   Einhorn, Lawrence H ^b   Neuberg, Donna ^b   Johnson, David H ^b   Smith, Julia L ^b   Hudes, Gary R ^b   Schultz, Stephen M ^b   Loehrer, Patrick J ^b  

^a University of Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

EID: 0027999651     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.11.2264     Document Type: Article

References (45)

1. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract; A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985
2. Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407, 1985
3. Sternberg CN, Yagoda A, Scher HI, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139:461-469, 1988
4. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
5. Loehrer PJ, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
6. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
7. Loehrer PJ, Elson P, Dreicer R, et al: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 12:483-488, 1994
8. Scher HI, Geller NL, Curley T, et al: Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 11:400-407, 1993
9. Seidman AD, Scher HI, Gabrilove JL, et al: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408-414, 1993
10. Witte R, Loehrer P, Dreicer R, et al. Ifosfamide in advanced urothelial carcinoma: An ECOG trial. Proc Am Soc Clin Oncol 12:230, 1993 (abstr)
11. Seidman AD, Scher HI, Heinemann MH, et al: Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68:2561-2565, 1991
12. Seligman PA, Crawford ED: Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst 83:1582-1584, 1991
13. Witte RS, Elson P, Khandaker J, et al: An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 73:688-691, 1994
14. Pollera CF, Ceribelli A, Crecco M, et al: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184, 1994
15. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
16. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
17. Forastiere AA, Neuberg D, Taylor SG, et al: Phase II evaluation of Taxol in advanced head and neck cancer: An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 12:277, 1993 (abstr)
18. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
19. Chang AY, Kim K, Glick J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993
20. Niell HB, Rangel C, Miller A, et al: The activity of antimicrotubular agents in human bladder tumor cell lines. Proc Am Assoc Cancer Res 34:202, 1993 (abstr)
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Boutan-Laroze A, Mahjoubi M, Droz JP, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. Eur J Cancer 27:1690-1694, 1991
23. Igawa M, Ohkuchi T, Ueki T, et al: Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144:662-665, 1990
24. Tannock I, Gospodarowicz M, Connolly J, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142:289-292, 1989
25. Logothetis CJ, Dexeus FH, Sella A, et al: Escalated therapy for refractory urothelial tumors: Methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 82:667-672, 1990
26. Forastiere AA: Use of paclitaxel (Taxol®) in squamous cell carcinoma of the head and neck. Semin Oncol 20:55-60, 1993
27. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
28. Merrin C: Treatment of advanced bladder cancer with cis-diamminedichloro-platinum II: A pilot study. J Urol 119:493-495, 1978
29. Yagoda A, Watson RC, Gonzalez-Vitale JC, et al: Cis-dichlorodiammineplatinum (II) in advanced bladder cancer. Cancer Treat Rep 60:917-923, 1976
30. Rossof AM, Talley RW, Stephens RL, et al: Phase II evaluation of cis-dichlorodiammineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs: A Southwest Oncology Group study. Cancer Treat Rep 63:1557-1564, 1979
31. Peters PC, O'Neill MR. Cisdiamminedichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma. J Urol 123:375-377, 1980
32. Herr HW: Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. J Urol 123:853-857, 1980
33. Oliver RTD, Newlands ES, Wiltshaw E, et al: A phase 2 study of cisplatinum in patients with recurrent bladder carcinoma. Br J Urol 53:444-447, 1981
34. Soloway MS, Ikard M, Ford K: Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer 47:476-480, 1981
35. DeLena M, Lorusso V, Iacobellis U, et al: Cis-diamminedichloroplatinum activity in bidimensionally measurable metastatic lesions of bladder carcinoma. Tumori 70:85-88, 1984
36. Khandekar JD, Elson PJ, DeWys WD, et al: Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3:539-545, 1985
37. Troner M, Birch R, Omura GA, et al: Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: A Southeastern Cancer Study Group trial. J Urol 137:660-662, 1987
38. Soloway MS, Einstein A, Corder MP, et al: A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. Cancer 52:767-772, 1983
39. Hillcoat BL, Raghavan D, Matthews J, et al: A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7:706-709, 1989
40. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
41. Rowinsky EK, Chaudry V, Forastiere AA, et al: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-2020, 1993
42. Tishler RB, Geard CR, Hall EJ, et al: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495-3497, 1992
43. Hei TK, Hall EJ: Taxol, radiation, and oncogenic transformation. Cancer Res 53:1368-1372, 1993
44. Choy H, Rodriguez FF, Koester S, et al: Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993
45. Steren A, Sevin B, Perras J, et al: Taxol as a radiation sensitizer: A flow cytometric study. Gynecol Oncol 50:89-93, 1993